BUZZ-BMO starts Novo Nordisk US shares with "overweight', Street-high PT

Reuters04-12

** BMO Capital Markets starts Novo Nordisk's U.S.-listed shares with "outperform" and a Street-high PT of $163, per LSEG data

** The Danish drugmaker' stock gains 1% to $126.66 after the EU drug regulator found no evidence that a class of diabetes and weight-loss drugs such as Novo's hugely popular Wegovy, are linked to suicidal thoughts

** BMO says "Our in-depth analysis of the growing obesity and adjacent metabolic disease market suggests both Lilly and Novo will remain the two entrenched players in this duopoly"

** BMO raises Eli Lilly's PT to $900

** Says Novo's expanded manufacturing with Catalent allows it to continue to supply the capacity-constrained market

** Adds NVO's multiple in-development obesity assets have strengthened its pipeline in a market the brokerage sees growing to over $130 billion in the U.S.

(Reporting by Puyaan Singh)

((Puyaan.Singh@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment